儲存: -15°C to -25°C/1 year(Do not lower than -25°C)
克隆性: Monoclonal
克隆號: PT0741R
特異性: Phospho-Smad2/3 (T8) Antibody detects endogenous levels of Smad2/3 protein only when phosphorylated at T8.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in 人 samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):PFtPP
基因名稱: SMAD2/SMAD3
蛋白名稱: Mothers against decapentaplegic homolog 2/3
別名: SMAD2;MADH2;MADR2;Mothers against decapentaplegic homolog 2;MAD homolog 2;Mothers against DPP homolog 2;JV18-1;Mad-related protein 2;hMAD-2;SMAD family member 2;SMAD 2;Smad2;hSMAD2;SMAD3;MADH3;Mothers against decapentaplegic
Organism-1: 人
基因ID-1: 4087;4088
SwissProt-1: Q15796;P84022
Organism-2: Mouse
基因ID-2: 17126;17127
Organism-3: Rat
基因ID-3: 29357;25631
SwissProt-3: O70436;P84025
細(xì)胞定位: Cytoplasm . Nucleus . Cytoplasmic and nuclear in the absence of TGF-beta. On TGF-beta stimulation, migrates to the nucleus when complexed with SMAD4 (PubMed:9865696, PubMed:21145499). On dephosphorylation by phosphatase PPM1A, released from the SMAD2/SMAD4 complex, and exported out of the nucleus by interaction with RANBP1 (PubMed:16751101, PubMed:19289081). Localized mainly to the nucleus in the early stages of embryo development with expression becoming evident in the cytoplasm at the blastocyst and epiblast stages (By similarity). .
組織表達(dá): Expressed at high levels in skeletal muscle, endothelial cells, heart and placenta.
儲存: -15°C to -25°C/1 year(Do not lower than -25°C)
克隆性: Monoclonal
克隆號: PT0741R
特異性: Phospho-Smad2/3 (T8) Antibody detects endogenous levels of Smad2/3 protein only when phosphorylated at T8.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in 人 samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):PFtPP
基因名稱: SMAD2/SMAD3
蛋白名稱: Mothers against decapentaplegic homolog 2/3
別名: SMAD2;MADH2;MADR2;Mothers against decapentaplegic homolog 2;MAD homolog 2;Mothers against DPP homolog 2;JV18-1;Mad-related protein 2;hMAD-2;SMAD family member 2;SMAD 2;Smad2;hSMAD2;SMAD3;MADH3;Mothers against decapentaplegic
Organism-1: 人
基因ID-1: 4087;4088
SwissProt-1: Q15796;P84022
Organism-2: Mouse
基因ID-2: 17126;17127
Organism-3: Rat
基因ID-3: 29357;25631
SwissProt-3: O70436;P84025
細(xì)胞定位: Cytoplasm . Nucleus . Cytoplasmic and nuclear in the absence of TGF-beta. On TGF-beta stimulation, migrates to the nucleus when complexed with SMAD4 (PubMed:9865696, PubMed:21145499). On dephosphorylation by phosphatase PPM1A, released from the SMAD2/SMAD4 complex, and exported out of the nucleus by interaction with RANBP1 (PubMed:16751101, PubMed:19289081). Localized mainly to the nucleus in the early stages of embryo development with expression becoming evident in the cytoplasm at the blastocyst and epiblast stages (By similarity). .
組織表達(dá): Expressed at high levels in skeletal muscle, endothelial cells, heart and placenta.